BeiGene and Revolution Medicines Enter Strategic Collaboration
On August 10, BeiGene announced a multi-faceted collaboration agreement with Revolution Medicines. Under the agreement, the two companies will collaborate on clinical trials to jointly evaluate combination therapies of some of BeiGene’s…
CSPC and AstraZeneca Joint Venture: A New Logic for MNCs to “Build Factories” in China
A British pharmaceutical giant has decided to build its most advanced production line in Shijiazhuang, a second-tier city on the North China Plain. On August 5, AstraZeneca and CSPC Pharmaceutical Group (or CSPC) signed an agreement to establish a joint…
Alphamab Oncology and Pathos reach international licensing agreement for TROP2/HER3 bispecific ADC.
On August 4, Alphamab Oncology (“Alphamab”) announced a licensing agreement with Pathos AI (“Pathos”) for its proprietary, “First-in-Class” TROP2/HER3 bispecific antibody-drug conjugate (ADC), JSKN016. Under the…